Vascular Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2005-01-01
- Employees
- 1
- Market Cap
- -
Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients
Phase 2
Completed
- Conditions
- Diabetic Nephropathy
- Interventions
- Drug: VPI-2690B high doseDrug: VPI-2690B low doseDrug: VPI-2690B medium doseDrug: Placebo to match VPI-2690B
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Vascular Pharmaceuticals, Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT02251067
© Copyright 2025. All Rights Reserved by MedPath